An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic

Ariel Fernández(Rice University), Gabriel Lopez‐Berestein(The University of Texas MD Anderson Cancer Center)
Journal of Clinical Investigation
December 3, 2007
Cited by 161


Related Papers